Dynamic Medical LLC

Dynamic Medical LLC was paid $1.03M by Medicaid between Apr 2019 and Apr 2022, across 42 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 20% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Virginia

Rank by total paid#20 of 78

Median peer was paid$37K

This provider vs. median28×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	114,378	$585K
2020	69,082	$372K
2021	1,429	$41K
2022	1,304	$35K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	20%	3,957	1,653	$202K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	9.5%	4,522	2,112	$99K
80376		6.0%	6,470	2,355	$62K
80346		3.7%	6,519	2,367	$38K
80361		3.0%	6,519	2,367	$31K
80355		3.0%	6,519	2,367	$31K
80323		2.9%	6,519	2,367	$30K
80345		2.5%	6,519	2,367	$26K
80368		2.4%	6,519	2,367	$24K
80324		2.4%	6,519	2,367	$24K
80367		2.4%	6,519	2,367	$24K
80372		2.4%	6,519	2,367	$24K

30 more codes

80321		2.4%	6,519	$24K
80332		2.4%	6,519	$24K
80365		2.4%	6,519	$24K
80348		2.4%	6,519	$24K
80360		2.4%	6,518	$24K
80364		2.4%	6,519	$24K
80366		2.4%	6,519	$24K
80357		2.3%	6,519	$24K
80337		2.3%	6,519	$24K
80373		2.3%	6,519	$24K
80338		2.3%	6,519	$24K
80369		2.3%	6,519	$24K
80354		2.3%	6,519	$24K
80305		1.8%	3,509	$19K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.7%	581	$18K
80353		1.5%	6,519	$15K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.5%	1,151	$15K
80358		<1%	6,520	$9K
83992		<1%	6,521	$9K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	124	$6K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	1,878	$5K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	524	$4K
87481		<1%	13	$385.99
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	69	$206.67
80048	Basic metabolic panel (calcium, ionized)	<1%	74	$93.05
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	46	$65.26
36415	Collection of venous blood by venipuncture	<1%	249	$60.29
80053	Comprehensive metabolic panel	<1%	19	$21.12
85027		<1%	17	$12.94
83036	Hemoglobin; glycosylated (A1C)	<1%	13	$9.71

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCOLE, WILLIAM (CHIEF OPERATING OFFICER)

Same official

Other billing entities under COLE, WILLIAM

Full network →

Provider	Location	Paid
Childrens Healthcare of Atlanta Cardiology INC	Atlanta, GA	$28.21M
Ohio Post-Acute Medical Services 1 INC	Englewood, OH	$519K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.